What Are Peptides?
Types, Uses, Benefits & Everything You Need to Know 2026
Peptides are short chains of amino acids — the same building blocks that make up proteins — that your body uses as signaling molecules to control hormones, tissue repair, immune function, and metabolism. Around 120 peptide drugs are approved globally, ranging from household names like semaglutide (Ozempic, Wegovy) to research compounds with compelling animal data but no completed human trials. The gap between those two categories matters enormously, and knowing which tier a peptide sits in before you use it is the most important thing this guide covers.
Key takeaways
- Peptides are chains of 2–50 amino acids. They sit between small-molecule drugs and full proteins in size, and they work through receptor-mediated cell signaling — not direct gene alteration like steroids.
- FDA-approved peptide drugs include semaglutide (Ozempic/Wegovy), teriparatide (Forteo), and insulin. These have multi-year safety data from large randomized controlled trials.
- Research peptides like BPC-157 and TB-500 have no completed human clinical trials. All current evidence comes from animal studies and small pilot studies.
- Growth hormone secretagogues — including CJC-1295, Ipamorelin, and GHRP-6 — appear on the 2026 WADA Prohibited List. Competitive athletes face sanctions for use, regardless of medical intent.
- On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of 19 previously restricted peptides would move from FDA Category 2 back to Category 1. As of March 2026, formal regulatory documentation has not been finalized. Verify current status at FDA.gov before use.
Before you start All compounded peptides require a valid prescription from a licensed physician and must be sourced from a licensed compounding pharmacy operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Regulatory status is actively changing in 2026 — verify each compound individually before use.
What are peptides? Structure, chemistry, and how they differ from proteins
Peptides are chains of 2–50 amino acids joined by covalent peptide bonds. They sit between small-molecule drugs (under 500 Da) and full proteins (over 10,000 Da / 50+ amino acids). Your body uses them as hormones, neuropeptides, antimicrobial agents, and tissue-repair messengers.
A 2024 review published in PMC (NCBI) found approximately 120 peptide drugs currently on the global market. The FDA has approved peptide drugs since insulin entered clinical use in 1923. Synthetic peptide analogs — including semaglutide, BPC-157, and CJC-1295 — either mimic or amplify these natural pathways.
| Property | Small molecule | Peptide | Protein |
|---|---|---|---|
| Size | Under 500 Da | 500–10,000 Da | Over 10,000 Da |
| Amino acid count | N/A | 2–50 AA | 50+ AA |
| Oral bioavailability | Generally high | Low for most | Very low |
| Specificity | Moderate | High | Very high |
| Half-life | Hours to days | Minutes to hours | Hours to weeks |
| Immunogenicity | Low | Low to moderate | Moderate to high |
Unlike steroids, which alter gene expression directly, peptides work through receptor-mediated signaling. When the body breaks down a peptide, the byproducts are amino acids — the same building blocks used throughout normal metabolism.
Peptide salt forms: acetate vs. TFA vs. free base
Peptides are supplied in three common salt forms: acetate, trifluoroacetate (TFA), and free base. The salt form affects purity, pH, and suitability for injection.
TFA is a byproduct of standard peptide synthesis. At higher concentrations, TFA residue can be cytotoxic — which is why injectable-grade peptides require TFA removal, typically confirmed by a certificate of analysis (COA). Acetate salt is the preferred form for injectable peptides because it is physiologically compatible and carries no TFA residue. Free base peptides lack any counterion and behave differently in solution depending on pH.
Confirm the salt form with your licensed pharmacy before use of any injectable compound.
Non-ribosomal peptides
Not all peptides are built by ribosomes. Non-ribosomal peptides (NRPs) are assembled by enzyme complexes and are generally more resistant to enzymatic breakdown. Clinically important NRPs include vancomycin (antibiotic), cyclosporin (immunosuppressant), and teixobactin (experimental antibiotic against drug-resistant bacteria).
Learn more about how peptide structure affects bioavailability and delivery method.
How peptides work
Peptides bind to receptors on cell surfaces — most commonly G-protein coupled receptors (GPCRs). When a peptide binds a GPCR, it triggers a downstream signaling cascade that changes what the cell does: producing a hormone, repairing tissue, or modulating inflammation. Over 40% of peptides that entered clinical trials since 2010 target GPCRs, according to Nature Reviews Drug Discovery.
The signaling chain looks like this:
Peptide → binds GPCR on cell surface → triggers intracellular signaling cascade → cell produces hormone / initiates repair / modulates immune response
This receptor-mediated mechanism is what distinguishes peptides from steroids. Steroids enter the cell nucleus and alter gene expression directly. Peptides stay outside and send a message. The difference has significant implications for side effects and reversibility.
Learn more about GPCR-mediated signaling and what it means for peptide safety.
Types of peptides and benefits by condition
Key takeaways for this section
- PeptideRx uses a three-tier grading system: Grade A (multiple human RCTs), Grade B (limited human trials or strong animal data), Grade C (primarily animal or in vitro data).
- Semaglutide for type 2 diabetes and obesity is Grade A — the only peptide class in this guide at that tier for the conditions covered here.
- BPC-157 and TB-500 are Grade C. Compelling animal data exists, but no completed human RCTs.
| Condition | Peptide(s) | Evidence tier | FDA status |
|---|---|---|---|
| Type 2 diabetes / obesity | Semaglutide (GLP-1 class) | Grade A | FDA-approved |
| Bone loss (osteoporosis) | Teriparatide (Forteo) | Grade A | FDA-approved |
| Skin / anti-aging (topical) | GHK-Cu, collagen peptides | Grade B | Not FDA-approved |
| Musculoskeletal repair | BPC-157, TB-500 | Grade C | Not FDA-approved |
| Gut / GI repair | BPC-157 | Grade C | Not FDA-approved |
| Cognitive / anxiety | Semax, Selank | Grade C | Not FDA-approved |
| Sleep regulation | DSIP | Grade C | Not FDA-approved |
| Immune support | Thymosin Alpha-1 | Grade B | Not FDA-approved |
PeptideRx rates the evidence for semaglutide in metabolic and weight management applications as Grade A. PeptideRx rates the evidence for BPC-157 and TB-500 in musculoskeletal and GI applications as Grade C.
Gut and GI repair
Body Protection Compound-157 (BPC-157) is a 15-amino acid synthetic peptide originally isolated from gastric juice. Animal studies show BPC-157 promotes gastric mucosal healing, reduces intestinal inflammation, and accelerates gut tissue repair.
A 2024 pilot study (Lee et al.) treated 12 women with severe interstitial cystitis using BPC-157 injections and reported 80–100% symptom resolution at 6 weeks with no adverse effects. That result is notable — but the study had no placebo group, which makes it impossible to separate the peptide’s effect from natural recovery or expectation.
This is the current state of BPC-157 human evidence: promising signals, no controlled trials.
Musculoskeletal repair
BPC-157 and TB-500 (Thymosin Beta-4 fragment) both promote angiogenesis (new blood vessel formation) and stimulate fibroblast activity, which supports tendon and ligament healing.
A 2024 systematic review in the Orthopaedic Journal of Sports Medicine (Pourmand et al.; PMC: 12313605) analyzed 36 preclinical studies from 1993 to 2024. BPC-157 consistently enhanced growth hormone receptor expression and reduced inflammatory cytokines across muscle, tendon, ligament, and bone injury animal models. One human study included in the review found that 7 of 12 patients with chronic knee pain reported significant relief lasting more than 6 months after a single BPC-157 injection.
Important: Angiogenesis — the same mechanism driving tissue repair — can theoretically accelerate tumor growth. See the safety section for a full discussion.
Skin and anti-aging
GHK-Cu (Glycyl-L-histidyl-L-lysine copper) stimulates collagen and elastin synthesis, acts as an antioxidant, and supports skin barrier repair. Topical GHK-Cu serums are widely available and considered generally well-tolerated in clinical settings.
The FDA banned GHK-Cu in injectable form in September 2023. Topical products remain available without prescription.
Collagen peptides (hydrolyzed collagen) have Grade B evidence for improving skin hydration and reducing wrinkle depth, based on several small randomized trials in humans.
Antimicrobial peptides (AMPs), including LL-37, are produced naturally by the skin and maintain barrier integrity. Dysregulation of LL-37 is linked to psoriasis, eczema, and acne. Prescription AMP formulations are in development but not yet widely available.
Metabolic and weight management
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a peptide that mimics the natural GLP-1 hormone released by the intestine after eating. The FDA approved semaglutide injection (Ozempic) for type 2 diabetes in December 2017, and approved the same molecule as Wegovy for chronic weight management in June 2021.
Semaglutide reduces blood sugar by stimulating insulin secretion, slows gastric emptying, and suppresses appetite via GLP-1 receptors in the brain, pancreas, and gut.
Neurological and cognitive function
Semax and Selank are synthetic neuropeptides studied primarily in Russia. Semax is thought to upregulate brain-derived neurotrophic factor (BDNF) and has been used clinically in Russia for stroke recovery. Selank has anxiolytic properties in animal models. Both are Grade C compounds in the United States — no completed large-scale human RCTs exist.
DSIP (Delta Sleep-Inducing Peptide) has been studied for sleep regulation and stress response. Evidence remains limited to animal studies and small open-label human trials.
Learn more about the evidence gap between Russian clinical use and US regulatory status for neuropeptides.
Who uses peptides and why
Athletes and physically active adults
Athletes use peptides primarily to support injury recovery and, in some cases, to stimulate growth hormone release. Growth hormone secretagogues (GHS) — including CJC-1295, Ipamorelin, and GHRP-6 — stimulate the pituitary gland to produce growth hormone in pulses, which supports muscle recovery, sleep quality, and body composition.
Critical disclosure for competitive athletes: The 2026 WADA Prohibited List (in force January 1, 2026) prohibits the entire GHS class both in and out of competition. Named prohibited substances include CJC-1295, sermorelin, tesamorelin, ipamorelin, GHRP-2, GHRP-6, MK-677 (ibutamoren), and Thymosin Beta-4 (TB-500). Athletes subject to WADA testing face sanctions for use regardless of medical intent. Verify the current status of any substance at the WADA official prohibited list before use. BPC-157 does not currently appear on the WADA Prohibited List, though USADA has noted it is unapproved for human clinical use.
Biohackers and longevity seekers
Biohackers use peptides including Epitalon and MOTS-c for longevity applications. Epitalon is studied for telomere maintenance and pineal gland regulation. MOTS-c is a mitochondria-derived peptide studied for metabolic function and cellular stress response. Both are Grade C evidence — interest is driven largely by early animal research rather than completed human trials.
Injury recovery patients
Patients with tendon tears, ligament injuries, and post-surgical recovery gaps use BPC-157 and TB-500 when conventional treatment has not resolved the condition. All clinical use of these peptides in the United States requires a valid prescription from a licensed physician and sourcing from a licensed compounding pharmacy.
Clinical patients (FDA-approved drugs)
Patients receiving FDA-approved peptide drugs — including semaglutide (Ozempic, Wegovy, Rybelsus), teriparatide (Forteo), abaloparatide (Tymlos), and ziconotide (Prialt) — represent the largest group of peptide users globally. These drugs have completed Phase I, II, and III clinical trials and carry FDA-approved indications with established dosing guidelines.
Learn more about FDA-approved peptide drugs and their approved indications.
Administration routes
Most therapeutic peptides require injection because digestive enzymes in the stomach and intestines break down peptide bonds before the peptide can reach the bloodstream. Of approximately 120 peptide drugs currently on the global market, only a small fraction are approved for oral use. Semaglutide (Rybelsus) achieves oral delivery by co-formulating with an absorption enhancer (SNAC) that protects it from gastric degradation.
| Route | Bioavailability | Onset | Examples | Best for |
|---|---|---|---|---|
| Subcutaneous injection | 80–99% | 30–90 min | BPC-157, Ipamorelin, Semaglutide | Most research and Rx peptides |
| Intramuscular injection | 80–99% | 20–60 min | TB-500 (some protocols) | Faster onset preference |
| Nasal spray | 10–30% | 15–40 min | Semax, PT-141, Oxytocin | Peptides with CNS targets |
| Sublingual | Variable | 15–30 min | Oxytocin, some custom formulations | Low-volume peptides |
| Oral | Low, generally 1–10% | 60–120 min | Semaglutide (Rybelsus), BPC-157 (GI-specific) | Gut-targeted applications only |
| Topical | Very low systemic | Hours | GHK-Cu, collagen peptides | Skin / cosmetic targets only |
Nasal and sublingual delivery
Semax is commonly delivered as a nasal spray in clinical settings in Russia, where it is an approved prescription drug. PT-141 (bremelanotide), FDA-approved for hypoactive sexual desire disorder in women (brand name Vyleesi), is delivered by subcutaneous injection. Oxytocin is available as a nasal spray through licensed compounding pharmacies under physician prescription.
Nasal delivery bypasses first-pass metabolism and allows some peptides to cross into the central nervous system more efficiently than peripheral injection.
Topical peptide delivery
Topical peptides face a fundamental barrier: skin is designed to keep large molecules out. Most peptides cannot penetrate the dermis without formulation engineering. Cosmetic peptide serums (GHK-Cu, Matrixyl) work primarily in the epidermis and upper dermis. Therapeutic-level delivery requires either specialized carrier systems or prescription formulations.
Learn more about peptide bioavailability by route and what it means for dosing.
Dosing, reconstitution, and storage
Important: All compounded peptide dosing must be determined by a licensed prescribing physician based on your weight, health status, and treatment goal. The ranges below reflect typical protocols from clinical settings and research — they are not prescribing recommendations. Do not self-administer compounded peptides without a valid prescription.
Clinical protocol frameworks
| Peptide | Typical clinical range | Frequency | Cycle length | Route |
|---|---|---|---|---|
| BPC-157 | 250–500 mcg/day | Once or twice daily | 4–12 weeks | Subcutaneous or oral |
| TB-500 | 2–10 mg/week | Weekly (loading), biweekly (maintenance) | 4–6 weeks loading | Subcutaneous or IM |
| CJC-1295 + Ipamorelin | 100–300 mcg each | Once daily (before sleep) | 8–12 weeks | Subcutaneous |
| GHK-Cu (topical) | Per product formulation | Once or twice daily | Ongoing | Topical |
| Semaglutide | 0.25–2.4 mg/week | Once weekly | Ongoing | Subcutaneous or oral |
| Semax | 200–900 mcg/day | Once daily | 2–4 weeks | Nasal |
Dosing for research peptides (BPC-157, TB-500, Semax) is not supported by large-scale human clinical trial data. Ranges above are drawn from physician clinical practice and small pilot studies.
Weight-based dosing
Some protocols use mcg per kilogram of body weight. BPC-157 animal studies commonly use 2–10 mcg/kg; human clinical practice varies. Weight-based dosing is more precise for injectable peptides where the therapeutic window may be narrow. A physician calculates the appropriate dose based on your weight and treatment indication.
Reconstitution: step-by-step
Compounded injectable peptides arrive as lyophilized (freeze-dried) powder in sealed glass vials. The powder must be reconstituted with bacteriostatic water (BAC water) before injection. BAC water contains 0.9% benzyl alcohol as a preservative, which prevents bacterial growth across multiple draws from the same vial.
Important: Do not use sterile water for multi-dose vials. Sterile water has no preservative and becomes a contamination risk after the first needle insertion.
What you need: peptide vial, BAC water vial, one 3–5 mL syringe for drawing water, insulin syringes (28–31 gauge, 0.5–1 mL) for dosing, 70% isopropyl alcohol swabs, nitrile gloves, and a clean flat surface.
Step 1 — Prepare your workspace. Clean a flat surface with isopropyl alcohol. Lay out all materials before opening any vials.
Step 2 — Sanitize both vials. Wipe the rubber stopper of both the peptide vial and the BAC water vial with an alcohol swab. Let each air dry for 10–15 seconds.
Step 3 — Draw the BAC water. Pull back the plunger to draw air equal to the volume of water you’ll extract. Insert the needle through the BAC water stopper, inject the air, then withdraw the calculated volume of water. Common volume: 1–2 mL for a 5 mg peptide vial.
Step 4 — Add water to the peptide vial. Angle the needle so it touches the inside glass wall. Inject the BAC water slowly, letting it run down the glass — not directly onto the powder. Direct force can denature (damage) the peptide structure.
Step 5 — Dissolve. Gently swirl the vial in a circular motion. Do not shake. The solution should turn clear within 1–5 minutes. Persistent cloudiness after 10 minutes — contact your dispensing pharmacy.
Step 6 — Calculate your dose in syringe units.
Using a standard U-100 insulin syringe (100 units = 1 mL):
- Concentration (mcg/mL) = Peptide amount in mcg ÷ BAC water volume in mL
- Injection volume (mL) = Desired dose (mcg) ÷ Concentration (mcg/mL)
- Syringe units = Injection volume (mL) × 100
Example: 5 mg vial reconstituted with 2 mL BAC water = 2,500 mcg/mL. A 500 mcg dose requires 0.2 mL = 20 units on a U-100 syringe.
Storage
| State | Storage method | Shelf life |
|---|---|---|
| Lyophilized (unreconstituted) | Room temperature, away from light | Up to 3 months |
| Lyophilized (unreconstituted) | Refrigerator (2–8°C / 36–46°F) | Up to 12 months |
| Reconstituted | Refrigerator (2–8°C / 36–46°F) | Up to 28 days |
| Reconstituted | Freezer | Do not freeze — damages peptide structure |
Label each reconstituted vial with the date of mixing. Discard if the solution becomes cloudy or develops visible particles.
Injection technique
Subcutaneous injection sites include the abdomen (2 inches from the navel), outer thigh, and flank. Intramuscular sites include the deltoid and gluteus. Rotate injection sites with each dose to reduce tissue irritation. Use a new sterile needle for every injection.
Learn more about subcutaneous injection technique and site rotation.
Side effects and safety
Key takeaways for this section
- The cancer/angiogenesis concern for BPC-157 and TB-500 is theoretical — mechanistically plausible but not demonstrated in human studies. It is a contraindication for patients with active malignancy or recent remission.
- Growth hormone secretagogues can worsen insulin resistance in patients with pre-existing metabolic disease.
- Injectable GHK-Cu was FDA-banned in September 2023 due to immunogenicity concerns. Topical formulations remain available.
Side effects by route
| Route | Common adverse effects | Serious risks | Mitigation |
|---|---|---|---|
| Subcutaneous injection | Bruising, redness, injection-site nodules | Infection, abscess | Sterile technique, site rotation |
| Intramuscular injection | Pain, bruising | Infection, nerve irritation | Proper needle length, trained technique |
| Nasal spray | Nasal irritation, headache | Rare allergic reactions | Dose reduction, antihistamine if needed |
| Topical | Contact dermatitis | None documented for GHK-Cu | Patch test before use |
| Oral | Nausea, GI upset | Varies by peptide | Dose with food, start low |
Cancer and angiogenesis risk
BPC-157 and TB-500 both promote angiogenesis — new blood vessel formation. This is necessary for tissue healing. It is also a hallmark of cancer: tumors use the same vascular growth mechanisms to expand and spread.
A 2024 pharmaceutical review (Jóźwiak et al., Pharmaceuticals, 2024) noted that BPC-157 increases expression of VEGFR2, a key receptor for vascular growth, in animal models. VEGF/VEGFR2 pathways are active in approximately half of human cancers, including ovarian cancer and melanoma. The review authors flagged this as theoretical — not proven — risk in humans.
No study has shown that BPC-157 or TB-500 causes cancer in humans. The concern is mechanistic: if undiagnosed cancer cells are present, pro-angiogenic peptides could theoretically support their growth. Physicians prescribing these compounds should screen patients for cancer history and elevated tumor markers before starting treatment. Patients with active malignancy or recent remission should not use pro-angiogenic peptides without thorough physician consultation.
Immunogenicity
Some peptide drugs trigger antibody formation (immunogenicity), which reduces efficacy over time or causes allergic reactions. The FDA’s September 2023 ban on injectable GHK-Cu was partly based on immunogenicity concerns. Anaphylaxis is a rare but serious risk with any injectable compound. Licensed compounding pharmacies minimize this risk through standardized purity testing, but zero risk cannot be guaranteed for research peptides without completed clinical trials.
Cardiovascular considerations
Growth hormone secretagogues (CJC-1295, Ipamorelin, GHRP-6) increase GH and IGF-1 levels, which can affect insulin sensitivity. Patients with pre-existing insulin resistance or type 2 diabetes should discuss GH secretagogue use with their physician. Elevated GH levels have also been associated with changes in blood pressure and left ventricular hypertrophy in cases of sustained supraphysiologic exposure.
Learn more about screening considerations before starting research peptides.
Legal and compliance status (2026)
Key takeaways for this section
- FDA Category 1 = compounding allowed with prescription. Category 2 = restricted from compounding.
- HHS announced reclassification of approximately 14 peptides from Category 2 back to Category 1 on February 27, 2026. As of March 2026, formal regulatory documentation has not been published. Verify at FDA.gov.
- Competitive athletes: the entire GHS class is WADA-prohibited in 2026. TB-500 is also prohibited. BPC-157 is not currently listed but is under monitoring.
| Peptide | FDA status (March 2026) | WADA 2026 status | Compounding access |
|---|---|---|---|
| Semaglutide (Ozempic/Wegovy) | FDA-approved | Not prohibited | Rx — brand or compounded |
| Teriparatide (Forteo) | FDA-approved | Not prohibited | Rx — brand |
| BPC-157 | Category 2 (reclassification pending) | Not listed (monitoring) | Restricted — verify current status |
| TB-500 (Thymosin Beta-4) | Category 2 (reclassification pending) | Prohibited (S2) | Restricted — verify current status |
| CJC-1295 | Not FDA-approved | Prohibited (S2) | Category 2 — restricted |
| Ipamorelin | Not FDA-approved | Prohibited (S2) | Category 2 — restricted |
| Thymosin Alpha-1 | Not FDA-approved | Not listed | Category 1 — compounding allowed |
| GHK-Cu (topical) | Not FDA-approved; injection banned | Not listed | Topical: widely available |
| Semax | Not FDA-approved | Not listed | Gray area — not formally scheduled |
Important: This table reflects the status as of March 2026. Regulatory status is changing. Always verify against FDA.gov and the WADA prohibited list before clinical or athletic use.
WADA and USADA status
The 2026 WADA Prohibited List (effective January 1, 2026) prohibits the following peptide classes under Section S2:
- All growth hormone releasing factors (including CJC-1293, CJC-1295, sermorelin, tesamorelin)
- All growth hormone secretagogues and mimetics (including ibutamoren/MK-677, ipamorelin, capromorelin, anamorelin)
- All GH-releasing peptides (including GHRP-1, GHRP-2, GHRP-3, GHRP-4, GHRP-5, GHRP-6, hexarelin)
- Thymosin Beta-4 and its derivatives (which includes TB-500)
- Growth hormone itself, its analogs, and fragments (including AOD-9604)
Athletes are strictly responsible for any prohibited substance found in their sample, regardless of intent. Testing detection windows for injectable peptides typically range from 12 hours to 4 days depending on the compound and detection method.
Military and Department of Defense
Department of Defense (DoD) service members face additional restrictions beyond WADA rules. DoD testing panels may differ from WADA panels, and even compounds not on the WADA list may appear in DoD testing. Treat all peptide compounds with caution and consult the DoD Prohibited Dietary Supplement Resource before use.
Learn more about peptide legal status by use case: clinical, athletic, and research.
Stacking and combinations
Stacking refers to using two or more peptides together to target complementary mechanisms. No randomized controlled trials have examined peptide stacking combinations. The rationale below is mechanistic — based on how each peptide works individually — not clinical evidence of synergy.
| Stack | Mechanism rationale | Evidence basis | Regulatory note |
|---|---|---|---|
| BPC-157 + TB-500 | BPC-157 targets mucosal and systemic repair; TB-500 targets actin regulation and vascular growth | Mechanistic + anecdotal | Both were Category 2 until 2026 reclassification (pending) |
| GHK-Cu + KPV | GHK-Cu stimulates collagen; KPV reduces inflammation | Mechanistic | Topical form widely available |
| CJC-1295 + Ipamorelin | GHRH analog + ghrelin mimetic — amplifies pulsatile GH release | Mechanistic + small clinical reports | WADA prohibited for competitive athletes |
BPC-157 and TB-500
BPC-157 enhances fibroblast activity and collagen synthesis. TB-500 promotes progenitor cell differentiation and vascular growth through actin regulatory pathways. The two are commonly combined at a 1:1 to 1:2 ratio (BPC-157 to TB-500). The rationale: BPC-157 targets tissue-level repair while TB-500 addresses vascular supply. No human RCT exists for this combination.
CJC-1295 and Ipamorelin
CJC-1295 is a growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary to produce growth hormone. Ipamorelin is a selective growth hormone secretagogue that mimics ghrelin. Together, they amplify pulsatile GH release more than either compound alone. Both are WADA-prohibited in 2026 for competitive athletes.
Learn more about peptide stacking rationale and the evidence gap.
Quality criteria and buying guide
All compounded peptides for clinical use should come from a licensed compounding pharmacy operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. The markers below determine whether a compound meets acceptable clinical quality.
What to look for:
- Certificate of analysis (COA): Every peptide lot should have a COA from a third-party laboratory confirming identity, purity, and absence of harmful contaminants.
- HPLC purity: High-performance liquid chromatography (HPLC) purity of at least 98% is the standard for injectable-grade peptides. Below 95% is below acceptable clinical quality.
- Mass spectrometry verification: Mass spec confirms molecular weight matches the peptide’s expected structure. HPLC alone cannot detect substituted or degraded peptides.
- Sterility testing: Injectable peptides require sterility testing per USP standards.
- Salt form disclosure: Acetate salt is preferred for injectables. TFA residuals should be confirmed removed to within safe thresholds.
- Cold-chain shipping: Lyophilized peptides should ship with ice packs and arrive cold.
Red flags:
- No COA, or COA from an in-house lab only (not third-party)
- No mass spectrometry verification
- HPLC purity below 95%
- Salt form not disclosed
- No physician prescription required for injectable compounds
- Shipping without temperature control
Alternatives
Pentadeca arginate (PDA)
Pentadeca arginate (PDA) is a structural analog of BPC-157 that uses an arginate salt form instead of the acetate form found in standard BPC-157. The arginate salt increases chemical stability and may improve storage shelf life. PDA emerged in the research literature in 2024–2025 as an alternative for patients and physicians seeking BPC-157-like tissue repair properties in a more stable compound. Human clinical data on PDA is extremely limited as of March 2026 — it is earlier in the research pipeline than BPC-157 itself.
Sermorelin vs. CJC-1295
Sermorelin is an FDA-approved growth hormone-releasing hormone (GHRH) analog with a shorter half-life than CJC-1295. Sermorelin requires daily injection due to its shorter duration of action (~10–20 minutes). CJC-1295 with DAC (Drug Affinity Complex) has a half-life of approximately 8 days and requires less frequent dosing.
Sermorelin has more human clinical data behind it than CJC-1295 and remains available through licensed compounding pharmacies under physician prescription. Both appear on the 2026 WADA Prohibited List.
| Peptide | Mechanism | Evidence tier | FDA status | Compounding access |
|---|---|---|---|---|
| PDA (Pentadeca Arginate) | Tissue repair — BPC-157 structural analog, arginate salt | Grade C | Not approved | Emerging; verify with pharmacy |
| Sermorelin | GHRH analog, stimulates pituitary GH release | Grade B | FDA-approved (compounding) | Available by prescription |
| CJC-1295 | Long-acting GHRH analog, 8-day half-life | Grade C | Not FDA-approved | Category 2 — restricted |
| TB-500 standalone | Thymosin Beta-4 fragment, actin regulation | Grade C | Not approved | Category 2 — restricted |
Learn more about sermorelin vs. CJC-1295 for growth hormone support.
The bottom line
Peptides span a wide range of evidence quality, and knowing which tier you’re looking at is the most important thing before any protocol decision. At one end are FDA-approved drugs like semaglutide, backed by large-scale randomized controlled trials in tens of thousands of patients. At the other end are research compounds like BPC-157 and TB-500 — compelling animal data and mechanistic rationale, no completed human RCTs.
The regulatory picture in 2026 is actively shifting, with HHS announcing reclassification of approximately 14 previously restricted peptides — but formal documentation hasn’t been published, which means access and legality need to be verified compound by compound. If you’re considering peptide therapy, start with a licensed physician who can evaluate your goals against the actual evidence tier for the compound you’re discussing.
Frequently Asked Questions
Are peptides the same as steroids?
No. Peptides are chains of amino acids that work through receptor-mediated signaling — they bind to cell surface receptors and trigger a downstream cascade. Steroids are lipid-based molecules that enter cells and directly alter gene expression. The mechanisms, side effect profiles, and legal classifications are all different.
Are peptides safe for long-term use?
It depends on the peptide. FDA-approved peptides like semaglutide have multi-year safety data from large clinical trials. Research peptides like BPC-157 and TB-500 have no long-term human safety data — the longest human studies run only a few weeks. Long-term safety for research peptides is genuinely unknown, and any physician prescribing them is working from a limited evidence base.
Can you take peptides orally?
A small number can be formulated for oral delivery — semaglutide (Rybelsus) is the most prominent example, using a co-formulation with an absorption enhancer (SNAC) to survive the digestive tract. Most peptides cannot be taken orally and maintain therapeutic levels because digestive enzymes break down peptide bonds before absorption. BPC-157 is used orally in some gut-specific protocols, but systemic bioavailability through oral dosing remains uncertain.
Which peptides are FDA-approved?
FDA-approved peptide drugs include semaglutide (Ozempic, Wegovy, Rybelsus) for diabetes and obesity, teriparatide (Forteo) and abaloparatide (Tymlos) for osteoporosis, ziconotide (Prialt) for severe chronic pain, linaclotide (Linzess) for irritable bowel syndrome, and insulin analogs for diabetes. Approximately 120 peptide drugs are approved globally across multiple therapeutic areas.
Do peptides build muscle?
Growth hormone secretagogues (CJC-1295, Ipamorelin, GHRP-6) stimulate pulsatile GH release, which supports lean body composition and recovery — but they do not directly build muscle the way anabolic steroids do. Collagen peptides support connective tissue repair but do not increase skeletal muscle mass. All GH secretagogues are prohibited by WADA for competitive athletes in 2026.
What is a peptide bond?
A peptide bond is the covalent link between two amino acids, formed when the carboxyl group of one amino acid reacts with the amino group of another. Peptide bonds have partial double-bond character, making them relatively rigid. Digestive enzymes break peptide bonds through hydrolysis — which is why most therapeutic peptides cannot be taken orally and remain systemically active.
How are peptides different from proteins?
Peptides contain 2–50 amino acids and typically have a molecular weight under 10,000 Da. Proteins contain 50 or more amino acids and fold into complex three-dimensional structures. Peptides generally have shorter half-lives than proteins and lower immunogenicity, making them easier to engineer as drugs.
What are bioregulator peptides?
Bioregulator peptides are short peptides — typically 2–4 amino acids — that regulate gene expression and cellular function. Epitalon (tetrapeptide Ala-Glu-Asp-Gly) is studied for telomere length maintenance and pineal gland regulation. MOTS-c is a mitochondria-derived peptide studied for metabolic regulation and cellular stress response. Both are Grade C evidence — primarily animal studies with limited human data.
Considering peptide therapy? Consult a licensed physician to discuss which protocols may be appropriate for your goals and health history. The evidence tier for the compound you’re evaluating matters as much as the compound itself.
References
- Al Musaimi O et al. FDA’s stamp of approval: Unveiling peptide breakthroughs in cardiovascular diseases, ACE, HIV, CNS, and beyond. Journal of Peptide Science. 2024. https://onlinelibrary.wiley.com/doi/full/10.1002/psc.3627
- Ponomareva LA et al. 2024 FDA TIDES (Peptides and Oligonucleotides) Harvest. PMC, NCBI. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11945313/
- THPdb2: compilation of FDA approved therapeutic peptides and proteins. ScienceDirect. 2024. https://www.sciencedirect.com/science/article/abs/pii/S1359644624001727
- Szychlinska MA et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. PMC. 2025. PMID: PMC12446177. https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/
- Pourmand A et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. Orthopaedic Journal of Sports Medicine. 2024. PMC: PMC12313605. https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/
- Jóźwiak M et al. Review of BPC-157’s effects on angiogenesis and cancer concerns. Pharmaceuticals. 2024.
- Lee E et al. BPC-157 for interstitial cystitis pilot study. Altern Ther Health Med. 2024.
- USADA. BPC-157: Experimental Peptide Creates Risk for Athletes. https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/
- WADA. 2026 List of Prohibited Substances and Methods. In force January 1, 2026. https://www.wada-ama.org/en/prohibited-list
- Amanecia Health. FDA Peptide Reclassification 2026: What It Means for Patients. March 2026. https://amaneciahealth.com/fda-peptide-reclassification-2026-what-patients-need-to-know/
- Semaglutide (Ozempic) FDA label. FDA.gov. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf
- Sharma D et al. Compare and Contrast the GLP-1 Receptor Agonists. StatPearls, NCBI Bookshelf. Updated 2024. https://www.ncbi.nlm.nih.gov/books/NBK572151/
- Semaglutide monograph. StatPearls, NCBI Bookshelf. Updated 2024. https://www.ncbi.nlm.nih.gov/books/NBK603723/
- Cleveland Clinic. GLP-1 Agonists: What They Are, How They Work & Side Effects. https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists
- FDA. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- GlobalRPH. BPC-157 And TB-500: Background, Indications, Efficacy, And Safety. November 2025. https://globalrph.com/2025/11/bpc-157-and-tb-500-background-indications-efficacy-and-safety/
- PeptideLaws.com. FDA Peptide Regulations 2026: What You Need to Know. March 2026. https://peptidelaws.com/news/fda-peptide-regulations-2026
- Cyclic Peptides: FDA-Approved Drugs and Their Oral Bioavailability and Metabolic Stability Tactics. WuXi AppTec DMPK. 2025. https://dmpkservice.wuxiapptec.com/articles/403-cyclic-peptides-fda-approved-drugs-and-their-oral-bioavailability-and-metabolic-stability-tactics/
- PeptideFox. Reconstitute Peptides with BAC Water: Step-by-Step Visual Guide. 2025. https://peptidefox.com/content/reconstitution
- NCBI Bookshelf. GLP-1 Receptor Agonists. StatPearls. Updated 2024. https://www.ncbi.nlm.nih.gov/books/NBK551568/
Disclaimer: This article is for educational purposes only. No peptide discussed on PeptideRx is FDA-approved for all uses described. Compounded peptides require a valid prescription from a licensed physician and must be sourced from a licensed compounding pharmacy operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. This content does not constitute medical advice.
PeptideRx content is medically reviewed by licensed physicians. Our evidence grading system (Grade A/B/C) reflects the quality and quantity of published research, not a recommendation for or against use.